Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 08/05 11:30:29 am
83.3 CHF   -0.06%
08/05Zymergen Names Chief Commercial Officer
MT
08/04GLOBAL MARKETS LIVE : Novartis, Apple, Commerzbank, Amgen, Lyft...
08/04NOVARTIS AG : Buy rating from UBS
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis to Produce Over 50 Million BioNTech-Pfizer COVID-19 Vaccine Doses in 2021

06/22/2021 | 11:23pm EDT


ę MT Newswires 2021
All news about NOVARTIS AG
08/05Zymergen Names Chief Commercial Officer
MT
08/04GLOBAL MARKETS LIVE : Novartis, Apple, Commerzbank, Amgen, Lyft...
08/04NOVARTIS AG : Buy rating from UBS
MD
08/03IONIS PHARMACEUTICALS : discovered pelacarsen continues to advance as potential ..
AQ
08/03BAUSCH HEALTH : Reports Q2 Revenue US$2.1 Billion; Plans To Pursue An IPO of Sol..
MT
08/03NOVARTIS : announces lift of partial clinical trial hold and plans to initiate a..
PU
08/03Novartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatm..
DJ
08/03NOVARTIS : Says FDA Lifts Partial Hold on Clinical Trial of Spinal Muscular Atro..
MT
08/03NOVARTIS : to Launch New Study of Neuromuscular Disease Drug After US FDA Lifts ..
MT
08/03PRESS RELEASE : Novartis announces lift of partial -2-
DJ
More news
Financials (USD)
Sales 2021 51 994 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 20,1x
Yield 2021 3,58%
Capitalization 224 B 224 B -
EV / Sales 2021 4,74x
EV / Sales 2022 4,43x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 91,83 $
Average target price 105,67 $
Spread / Average Target 15,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.42%223 691
JOHNSON & JOHNSON10.36%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.41%252 960
ELI LILLY AND COMPANY56.47%237 950
NOVO NORDISK A/S43.21%222 926